Seqirus has signed contracts with the European Commission and 15 European Union Member States to supply pandemic influenza vaccines as part of the response to a pandemic emergency.
It is the first influenza vaccine manufacturer to sign pandemic contracts under the EU joint procurement framework.
The European Centre for Disease Prevention and Control estimates that a severe pandemic could infect up to a quarter of the population of the European Union, with many millions of cases and tens of thousands of deaths.1
“According to the WHO, influenza remains one of the world’s greatest public health challenges and the question is not whether we will have another pandemic, but when. We are committed to working with our partners to protect people around the world by providing rapid access to influenza vaccines during a pandemic emergency,” said Gordon Naylor, President, Seqirus.
The development of the EU joint procurement framework was driven by the H1N1 influenza pandemic in 2009, which highlighted the lack of consistency in access to pandemic vaccines between EU countries.
The WHO’s Global Influenza Strategy for 2019 – 2030 states that a severe pandemic can result in widespread social and economic effects, including a loss of national economic productivity and severe economic burdens on affected citizens and communities.2
Seqirus is committed to working with key stakeholders in public health to develop a range of effective pandemic preparedness solutions, including stockpiling vaccines for first responders to help protect communities and mitigate the potentially devastating economic and social impact of an influenza pandemic.
References
- European Centre for Disease Prevention and Control. (2019) Questions and answers on influenza pandemics. https://ecdc.europa.eu/en/pandemic-influenza/facts/questions-and-answers. Accessed March 2019.
- WHO. Global influenza strategy 2019-2030. https://apps.who.int/iris/bitstream/handle/10665/311184/9789241515320-en…. Accessed March 2019.
